ArticleCancer science2011
Microarray analysis identifies versican and CD9 as potent prognostic markers in gastric gastrointestinal stromal tumors.
Article in Cancer science, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Prognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Tetraspanins in digestive‑system cancers: Expression, function and therapeutic potential (Review).Molecular medicine reports · 2024Review
- Roles of Proteoglycans and Glycosaminoglycans in Cancer Development and Progression.International journal of molecular sciences · 2020Review
- High expression of VCAN is an independent predictor of poor prognosis in gastric cancer.The Journal of international medical research · 2020Article
- GeneExpressScore Signature: a robust prognostic and predictive classifier in gastric cancer.Molecular oncology · 2018Article
- Identification of molecular genetic contributants to canine cutaneous mast cell tumour metastasis by global gene expression analysis.PloS one · 2018Article
- CD63 and GLUT-1 Overexpression Could Predict a Poor Clinical Outcome in GIST: A Study of 54 Cases with Follow-Up.Gastroenterology research and practice · 2016Article
- Molecular classification and prediction in gastric cancer.Computational and structural biotechnology journal · 2015Review
- Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.British journal of pharmacology · 2014Review
- The wound healing, chronic fibrosis, and cancer progression triad.Physiological genomics · 2014Review
- Expression and clinicopathological significance of CD9 in gastrointestinal stromal tumor.Journal of Korean medical science · 2013Article
- Article
- Embryonic stem cell markers.Molecules (Basel, Switzerland) · 2012Review
- Correlation of dynamic PET and gene array data in patients with gastrointestinal stromal tumors.TheScientificWorldJournal · 2012Article
- Interleukin-11 promotes the progress of gastric carcinoma via abnormally expressed versican.International journal of biological sciences · 2012Article
- Identification of DNA methylation changes associated with human gastric cancer.BMC medical genomics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the main cause of gastrointestinal stromal tumor (GIST) is gain-of-function mutations in the c-kit gene in the interstitial cells of Cajal, concomitant genetic or epigenetic changes other than c-kit appear to occur in the development of metastasis. We sought to identify the genes involved in the metastatic process of gastric GIST. Microarray analysis was performed to compare gene expressions between three gastric GIST and four metastatic liver GIST. Expression levels were higher for 165 genes and lower for 146 genes in metastatic liver GIST. The upregulation of five oncogenes and downregulation of four tumor suppressor genes including versican and CD9 were confirmed by quantitative reverse transcriptional PCR. Immunohistochemistry in 117 GIST revealed that protein levels of versican and CD9 were higher and lower, respectively, in metastatic GIST. High expression of versican and low expression of CD9 in 104 primary gastric GIST correlated with poor disease-free survival (P = 0.0078 and P = 0.0018). In addition to the c-kit gene mutation, genetic or epigenetic changes other than c-kit play important roles in the metastatic process. In particular, versican and CD9 are potential prognostic markers in gastric GIST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.